Skip to main navigation
Viridian Theraputics

ENGINEERING MEDICINES TO IMPROVE PATIENT CARE

Menu
  • About Viridian
    • Leadership
    • Board of Directors
  • Pipeline
    • Approach
    • History of IGF1R
    • Scientific Presentations
  • Patients
    • About TED
    • Clinical Trials
  • Careers
  • Investors
    • News and Events
      • News Releases
      • Scientific Presentations
      • Events and Presentations
    • Corporate Governance
      • Governance Documents
      • Leadership
      • Board of Directors
      • Committee Composition
    • Financials and Filings
      • SEC Filings
    • Stock Information
      • Analyst Coverage
      • Stock Quote & Chart
    • Investor Resources
      • Email Alerts
  • Contact

ENGINEERING MEDICINES TO IMPROVE PATIENT CARE

Investors

News Releases

January 4, 2022
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration
  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Displaying 11 - 11 of 11
Viridian Theraputics

Copyright© 2022 Viridian Therapeutics Inc. All Rights Reserved

Terms of Use Privacy Policy Careers